Look to CEL-SCI to Deliver Phase III Results in 2018 for Worldwide Approval of Head & Neck Cancer Immunotherapy
Top line results may soon be in at CEL-SCI, which concluded patient enrollment and dosing in the world's largest Phase III trial in the treatment of head and neck cancer. Between 2011 and 2016, 928 patients were enrolled and treated. According to the study's protocol, the effectiveness of CEL-SCI's drug in prolonging life can only be judged after 298 of the enrolled patients have died, since the FDA wants to see survival benefit. The number of deaths, or 'events', as...
View full press release